Literature DB >> 25395034

A contemporary survival analysis of individuals with cystic fibrosis: a cohort study.

Anne L Stephenson1, Melissa Tom2, Yves Berthiaume3, Lianne G Singer4, Shawn D Aaron5, G A Whitmore6, Sanja Stanojevic7.   

Abstract

Previously established predictors of survival may no longer apply in the current era of cystic fibrosis (CF) care. Our objective was to identify risk factors associated with survival in a contemporary CF population. We used the Canadian CF Registry, a population-based cohort, to calculate median age of survival and summarise patient characteristics from 1990 to 2012. Clinical, demographic and geographical factors, and survival were estimated for a contemporary cohort (2000-2012) using Cox proportional hazards models. There were 5787 individuals in the registry between 1990 and 2012. Median survival age increased from 31.9 years (95% CI 28.3-35.2 years) in 1990 to 49.7 years (95% CI 46.1-52.2 years) in the most current 5-year window ending in 2012. Median forced expiratory volume in 1 s improved (p=0.04) and fewer subjects were malnourished (p<0.001) over time. Malnourished patients (hazard ratio (HR) 2.1, 95% CI 1.6-2.8), those with multiple exacerbations (HR 4.5, 95% CI 3.2-6.4) and women with CF-related diabetes (HR 1.8, 95% CI 1.2-2.7) were at increased risk of death. Life expectancy in Canadians with CF is increasing. Modifiable risk factors such as malnutrition and pulmonary exacerbations are associated with an increased risk of death. The sex gap in CF survival may be explained by an increased hazard for death in women with CF-related diabetes.
Copyright ©ERS 2015.

Entities:  

Mesh:

Year:  2014        PMID: 25395034     DOI: 10.1183/09031936.00119714

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  45 in total

1.  Cardiorespiratory and sensory responses to exercise in adults with mild cystic fibrosis.

Authors:  Bradley S Quon; Sabrina S Wilkie; Yannick Molgat-Seon; Michele R Schaeffer; Andrew H Ramsook; Pearce G Wilcox; Jordan A Guenette
Journal:  J Appl Physiol (1985)       Date:  2015-10-01

2.  Molecular Heterogeneity in Cystic Fibrosis.

Authors:  Hasret A Civan; Serhat Seyhan
Journal:  J Pediatr Genet       Date:  2020-02-17

Review 3.  Chest imaging in cystic fibrosis studies: What counts, and can be counted?

Authors:  Rhonda Szczesniak; Lidija Turkovic; Eleni-Rosalina Andrinopoulou; Harm A W M Tiddens
Journal:  J Cyst Fibros       Date:  2016-12-28       Impact factor: 5.482

4.  Bespoke Babies: Genome Editing in Cystic Fibrosis Embryos.

Authors:  Kyle B Brothers; Mary Devereaux; Robert M Sade
Journal:  Ann Thorac Surg       Date:  2019-05-29       Impact factor: 4.330

5.  Cystic Fibrosis: The Dawn of a New Therapeutic Era.

Authors:  Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2017-04-15       Impact factor: 21.405

Review 6.  Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Authors:  Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz
Journal:  J Cyst Fibros       Date:  2019-03-27       Impact factor: 5.482

7.  A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts.

Authors:  Jenna Sykes; Sanja Stanojevic; Christopher H Goss; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Anne L Stephenson
Journal:  J Clin Epidemiol       Date:  2015-10-03       Impact factor: 6.437

8.  In statistics we trust: Towards the careful derivation and interpretation of meaningful survival estimates in cystic fibrosis.

Authors:  N Mayer-Hamblett; D Polineni; S L Heltshe
Journal:  J Cyst Fibros       Date:  2018-02-01       Impact factor: 5.482

9.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

10.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.

Authors:  Wen Ye; Michael R Narkewicz; Daniel H Leung; Wikrom Karnsakul; Karen F Murray; Estella M Alonso; John C Magee; Sarah Jane Schwarzenberg; Alexander Weymann; Jean P Molleston
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.